title: Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
abstract: The aim of this study was to investigate the efficacy and safety of the extended use of platinum-based doublet chemotherapy (PT-DC) plus endostatin in patients with advanced nonsmall cell lung cancer (NSCLC).We performed a retrospective analysis of 200 newly diagnosed advanced NSCLC patients who had received at least 1 cycle of endostatin plus PT-DC between September 2009 and November 2014. Of these patients, 155 received 4 or more cycles of therapy (the extended therapy group), while 45 received less than 4 cycles of therapy (the control group). Clinical tumor responses, progression-free survival (PFS), overall survival (OS), and toxicity profiles were recorded and retrospectively analyzed.In the extended therapy group, 67 patients (43.2%) achieved a best overall response rate of partial response (PR), while in the control group, 13 patients (28.9%) had a best overall response rate of PR. After a median follow-up of 15.9 months, the median PFS and OS were 8.0 and 23.1 months in the extended arm and 5.8 and 14.0 months in the control arm, respectively. There were statistically significant differences in median PFS and OS between these 2 arms. Hematologic and gastrointestinal toxicities occurred more frequently in the extended therapy group, but no statistically significant difference was detected in grade 3 to 4 toxicities overall between these 2 groups.In conclusion, extended treatment using endostatin combined with PT-DC can provide additional survival benefits and satisfactory toxicity profiles in previously untreated patients with NSCLC, which merits further evaluation in a larger prospective study.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Weiheng
authors.initials: W
authors.lastname: Hu
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.forename: Jun
authors.initials: J
authors.lastname: Nie
authors.forename: Ling
authors.initials: L
authors.lastname: Dai
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Chen
authors.forename: Xiangjuan
authors.initials: X
authors.lastname: Ma
authors.forename: Guangming
authors.initials: G
authors.lastname: Tian
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.forename: Sen
authors.initials: S
authors.lastname: Han
authors.forename: Jindi
authors.initials: J
authors.lastname: Han
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Jieran
authors.initials: J
authors.lastname: Long
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D043169:Endostatins / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000068437:Pemetrexed / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D043169:Endostatins; D009944:Organoplatinum Compounds; D000068437:Pemetrexed; D003841:Deoxycytidine; D000077146:Irinotecan; C053989:nedaplatin; D002945:Cisplatin; D002166:Camptothecin; D000093542:Gemcitabine